| High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells JA Clara, ER Levy, R Reger, S Barisic, L Chen, E Cherkasova, ... Journal for immunotherapy of cancer 10 (2), 2022 | 25 | 2022 |
| Graft-versus-solid-tumor effect: from hematopoietic stem cell transplantation to adoptive cell therapies S Barisic, RW Childs Stem Cells 40 (6), 556-563, 2022 | 9 | 2022 |
| A phase I study of HERV-E TCR transduced autologous T Cells (HERV-E TCR T Cells) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) R Nadal, E Cherkasova, S Barisic, D Granadier, G Aue, B Wells, G Hawks, ... Annals of Oncology 29, viii329, 2018 | 2 | 2018 |
| T cell receptor-engineered T cells targeting a human endogenous retrovirus in kidney cancer. S Barisic, EM Brahmbhatt, E Cherkasova, R Nadal, U Savani, S Pierre, ... Journal of Clinical Oncology 41 (16_suppl), 4542-4542, 2023 | 1 | 2023 |
| Phase I results of human endogenous retrovirus type-E (HERV-E) TCR transduced T-cells in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC). R Nadal, S Barisic, GM Scurti, E Cherkasova, L Chen, K Wood, SL Highfill, ... Journal of Clinical Oncology 41 (16_suppl), 2549-2549, 2023 | 1 | 2023 |
| Targeted mass spectrometry provides direct evidence of a human endogenous retrovirus type E (HERV-E) antigen presented on the surface of clear cell renal cell carcinoma cells S Barisic, E Cherkasova, Y Chen, S Pierre, RW Childs Cancer Research 81 (13_Supplement), 1891-1891, 2021 | 1 | 2021 |
| Improving killing of renal cell carcinoma through the combined effects of TCR engineered CD4+ and CD8+ T cells M Igboko, L Chen, S Barisic, E Cherkasova, D Allan, M Chakraborty, ... Cancer Research 84 (6_Supplement), 3601-3601, 2024 | | 2024 |
| Final results of a phase I trial of HERV-E TCR transduced T cells for the treatment of HLA-A* 11 patients with metastatic clear cell renal cell carcinoma (mccRCC). R Nadal, S Barisic, GM Scurti, E Cherkasova, L Chen, K Wood, SL Highfill, ... Journal of Clinical Oncology 42 (4_suppl), 435-435, 2024 | | 2024 |
| Ablation of an immunogenic human endogenous retrovirus in renal cell carcinoma cells through dual-guide CRISPR-Cas9 genome editing L Chen, E Cherkasova, S Pierre, S England, M Igboko, J Clara, S Barisic, ... Cancer Research 83 (7_Supplement), 5210-5210, 2023 | | 2023 |
| The Costimulatory Signal Domains 4-1BB and CD3ζ Do Not Improve the Function of CD16A Chimeric Antigen Receptor Transduced NK Cells L Chen, V Li, D Allan, R Reger, E Cherkasova, S Pierre, S Barisic, ... Cancer Research 79 (13_Supplement), 1434-1434, 2019 | | 2019 |
